Loading...
Ono Pharmaceutical Co., Ltd.
OPHLY•PNK
Healthcare
Drug Manufacturers - General
$3.67
$-0.07(-1.87%)
Ono Pharmaceutical Co., Ltd. (OPHLY) Financial Performance & Income Statement Overview
Review Ono Pharmaceutical Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-3.14%
↓ 3.14%
Operating Income Growth
-61.14%
↓ 61.14%
Net Income Growth
-60.89%
↓ 60.89%
Operating Cash Flow Growth
-25.48%
↓ 25.48%
Operating Margin
12.34%
↑ 12.34%
Gross Margin
69.61%
↑ 69.61%
Net Profit Margin
10.28%
↑ 10.28%
ROE
6.27%
↑ 6.27%
ROIC
6.56%
↑ 6.56%
Ono Pharmaceutical Co., Ltd. (OPHLY) Income Statement & Financial Overview
Review Ono Pharmaceutical Co., Ltd.'s (OPHLY) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $112.31B | $134.22B | $122.66B | $117.67B |
| Cost of Revenue | $45.24B | $45.84B | $27.21B | $29.67B |
| Gross Profit | $67.07B | $88.39B | $95.46B | $88.004B |
| Gross Profit Ratio | $0.60 | $0.66 | $0.78 | $0.75 |
| R&D Expenses | $42.79B | $38.27B | $39.95B | $28.86B |
| SG&A Expenses | $31.93B | $35.31B | $30.54B | $27.89B |
| Operating Expenses | $74.73B | $73.51B | $70.48B | $57.31B |
| Total Costs & Expenses | $119.96B | $119.35B | $97.69B | $86.98B |
| Interest Income | $635.00M | $1.86B | $0.00 | $2.69B |
| Interest Expense | $2.46B | $0.00 | $3.87B | $75.00M |
| Depreciation & Amortization | $8.73B | $9.17B | $4.62B | $4.38B |
| EBITDA | -$1.64B | $24.05B | $29.81B | $35.07B |
| EBITDA Ratio | -$0.01 | $0.18 | $0.24 | $0.30 |
| Operating Income | -$7.65B | $14.87B | $24.97B | $30.69B |
| Operating Income Ratio | -$0.07 | $0.11 | $0.20 | $0.26 |
| Other Income/Expenses (Net) | -$5.18B | $2.53B | -$3.65B | $2.62B |
| Income Before Tax | -$12.83B | $17.40B | $21.32B | $33.31B |
| Income Before Tax Ratio | -$0.11 | $0.13 | $0.17 | $0.28 |
| Income Tax Expense | -$6.34B | $2.51B | $4.52B | $8.47B |
| Net Income | -$6.54B | $14.95B | $16.85B | $24.79B |
| Net Income Ratio | -$0.06 | $0.11 | $0.14 | $0.21 |
| EPS | -$13.93 | $31.81 | $35.90 | $52.79 |
| Diluted EPS | -$14.06 | $31.81 | $35.90 | $52.75 |
| Weighted Avg Shares Outstanding | $465.56M | $469.99M | $469.68M | $469.64M |
| Weighted Avg Shares Outstanding (Diluted) | $469.76M | $469.99M | $469.68M | $470.03M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan